|
1
|
Cook DP and Vanderhyden BC: Ovarian cancer
and the evolution of subtype classifications using transcriptional
profilingdagger. Biol Reprod. 101:645–658. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Kroeger PT Jr and Drapkin R: Pathogenesis
and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol.
29:26–34. 2017. View Article : Google Scholar
|
|
3
|
Bowtell DD, Böhm S, Ahmed AA, Aspuria PJ,
Bast RC Jr, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, et
al: Rethinking ovarian cancer II: Reducing mortality from
high-grade serous ovarian cancer. Nat Rev Cancer. 15:668–679. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Koutsaki M, Libra M, Spandidos DA and
Zaravinos A: The miR-200 family in ovarian cancer. Oncotarget.
8:66629–66640. 2017. View Article : Google Scholar
|
|
5
|
Yang WL, Lu Z and Bast RC Jr: The role of
biomarkers in the management of epithelial ovarian cancer. Expert
Rev Mol Diagn. 17:577–591. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Colombo N, Sessa C, du Bois A, Ledermann
J, McCluggage WG, McNeish I, Morice P, Pignata S, Ray-Coquard I,
Vergote I, et al: ESMO-ESGO consensus conference recommendations on
ovarian cancer: Pathology and molecular biology, early and advanced
stages, borderline tumours and recurrent diseasedagger. Ann Oncol.
30:672–705. 2019. View Article : Google Scholar
|
|
7
|
Zhang J, Jiang TY, Jiang BG, Yang C, Tan
YX, Yang N, Pan YF, Ding ZW, Yang GZ, Wu MC, et al: RMP predicts
survival and adjuvant TACE response in hepatocellular carcinoma.
Oncotarget. 6:3432–3442. 2015. View Article : Google Scholar
|
|
8
|
Li Y, Jiang X, Yan X and Wang Y:
Upregulation of SIX4 indicates poor clinical outcome and promotes
tumor growth and cell metastasis in esophageal squamous cell
carcinoma. Thorac Cancer. 12:752–759. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sun X, Ma J, Chen Q, Hou Z, Luo X, Wang G,
Wang J, Hu J and Cao Z: SIX4 promotes metastasis through STAT3
activation in breast cancer. Am J Cancer Res. 10:224–236.
2020.PubMed/NCBI
|
|
10
|
Na XY, Shang XS, Zhao Y, Ren PP and Hu XQ:
miR-203a functions as a tumor suppressor in bladder cancer by
targeting SIX4. Neoplasma. 66:211–221. 2019. View Article : Google Scholar
|
|
11
|
Tang X, Yang Y, Song X, Liu X, Wang X,
Huang F, Li Y, Chen F and Wan H: SIX4 acts as a master regulator of
oncogenes that promotes tumorigenesis in non-small-cell lung cancer
cells. Biochem Biophys Res Commun. 516:851–857. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Johnston MJ, Bar-Cohen S, Paroush Z and
Nystul TG: Phosphorylated Groucho delays differentiation in the
follicle stem cell lineage by providing a molecular memory of EGFR
signaling in the niche. Development. 143:4631–4642. 2016.
|
|
13
|
Taniuchi K, Furihata M, Hanazaki K, Saito
M and Saibara T: IGF2BP3-mediated translation in cell protrusions
promotes cell invasiveness and metastasis of pancreatic cancer.
Oncotarget. 5:6832–6845. 2014. View Article : Google Scholar
|
|
14
|
Liu H, Zeng Z, Afsharpad M, Lin C, Wang S,
Yang H, Liu S, Kelemen LE, Xu W, Ma W, et al: Overexpression of
IGF2BP3 as a potential oncogene in ovarian clear cell carcinoma.
Front Oncol. 9:15702019. View Article : Google Scholar
|
|
15
|
Hsu KF, Shen MR, Huang YF, Cheng YM, Lin
SH, Chow NH, Cheng SW, Chou CY and Ho CL: Overexpression of the
RNA-binding proteins Lin28B and IGF2BP3 (IMP3) is associated with
chemoresistance and poor disease outcome in ovarian cancer. Br J
Cancer. 113:414–424. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li C, Tang Z, Zhang W, Ye Z and Liu F:
GEPIA2021: Integrating multiple deconvolution-based analysis into
GEPIA. Nucleic Acids Res. 49:W242–W246. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li JH, Liu S, Zhou H, Qu LH and Yang JH:
StarBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA
interaction networks from large-scale CLIP-Seq data. Nucleic Acids
Res. 42:D92–D97. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Xiao H, Zheng Y, Chen J and Shen H:
miR-198 inhibits proliferation, invasion and migration of ovarian
cancer cells by regulating the PI3K/Akt signaling pathway. Acta
Biochim Pol. 68:673–677. 2021.
|
|
20
|
Viallard C and Larrivee B: Tumor
angiogenesis and vascular normalization: Alternative therapeutic
targets. Angiogenesis. 20:409–426. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Unterleuthner D, Neuhold P, Schwarz K,
Janker L, Neuditschko B, Nivarthi H, Crncec I, Kramer N, Unger C,
Hengstschläger M, et al: Cancer-associated fibroblast-derived WNT2
increases tumor angiogenesis in colon cancer. Angiogenesis.
23:159–177. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Grunewald T and Ledermann JA: Targeted
therapies for ovarian cancer. Best Pract Res Clin Obstet Gynaecol.
41:139–152. 2017. View Article : Google Scholar
|
|
23
|
Yousefi M, Dehghani S, Nosrati R, Ghanei
M, Salmaninejad A, Rajaie S, Hasanzadeh M and Pasdar A: Current
insights into the metastasis of epithelial ovarian cancer-hopes and
hurdles. Cell Oncol (Dordr). 43:515–538. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
He L, Zhu W, Chen Q, Yuan Y, Wang Y, Wang
J and Wu X: Ovarian cancer cell-secreted exosomal miR-205 promotes
metastasis by inducing angiogenesis. Theranostics. 9:8206–8220.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Folkman J: Tumor angiogenesis: Therapeutic
implications. N Engl J Med. 285:1182–1186. 1971. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao
HL, Li H, Zhang SR, Xu JZ, Qi ZH, et al: Angiogenesis in pancreatic
cancer: Current research status and clinical implications.
Angiogenesis. 22:15–36. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Ramjiawan RR, Griffioen AW and Duda DG:
Anti-angiogenesis for cancer revisited: Is there a role for
combinations with immunotherapy? Angiogenesis. 20:185–204. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
He Q, Lin Z, Wang Z, Huang W, Tian D, Liu
M and Xia L: SIX4 promotes hepatocellular carcinoma metastasis
through upregulating YAP1 and c-MET. Oncogene. 39:7279–7295. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sun X, Hu F, Hou Z, Chen Q, Lan J, Luo X,
Wang G, Hu J and Cao Z: SIX4 activates Akt and promotes tumor
angiogenesis. Exp Cell Res. 383:1114952019. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Yang Z, Wang T, Wu D, Min Z, Tan J and Yu
B: RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and
angiogenesis in colon cancer. J Exp Clin Cancer Res. 39:2032020.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kobel M, Xu H, Bourne PA, Spaulding BO,
Shih IeM, Mao TL, Soslow RA, Ewanowich CA, Kalloger SE, Mehl E, et
al: IGF2BP3 (IMP3) expression is a marker of unfavorable prognosis
in ovarian carcinoma of clear cell subtype. Mod Pathol. 22:469–475.
2009. View Article : Google Scholar
|
|
32
|
Noske A, Faggad A, Wirtz R, Darb-Esfahani
S, Sehouli J, Sinn B, Nielsen FC, Weichert W, Buckendahl AC, Röske
A, et al: IMP3 expression in human ovarian cancer is associated
with improved survival. Int J Gynecol Pathol. 28:203–210. 2009.
View Article : Google Scholar
|
